Overview

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-09
Target enrollment:
Participant gender:
Summary
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
Phase:
NA
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
axicabtagene ciloleucel